Oncometabolite produced by mutant isocitrate dehydrogenase 1 (IDH1) and IDH2. Inhibits KDM4A in murine embryonic fibroblasts resulting in activation of mTOR. Also activates NF-κ
B in bone marrow stromal cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Chen et al.
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway.
Carbonneau et al.